Inactief instrument

Andere talen Bellerophon Therapeutics LLC Nasdaq

Aandelen

slotkoers Nasdaq Andere beurzen
-	-

04/03	Bellerophon Therapeutics, Inc. Kondigt het ontslag aan van Mary Ann Cloyd en Scott Bruder als leden van de Raad van Bestuur	CI
2023	Bellerophon Therapeutics, Inc. kondigt wijzigingen aan in het management	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

North American Morning Briefing : Stock Futures -2-	02/05
North American Morning Briefing : More Tech -2-	25/04
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04
North American Morning Briefing : Focus Turns to -2-	04/04
North American Morning Briefing : Stocks Set for -2-	28/03
Bellerophon Therapeutics, Inc. Announces Resignation of Mary Ann Cloyd and Scott Bruder as Members of Board of Directors	04/03
Bellerophon Therapeutics, Inc. Announces Executive Changes	21/11
Bellerophon Therapeutics, Inc. Announces Executive Changes	21/11
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	20/11
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from S&P TMI Index	18-10-23
Bellerophon Therapeutics Insider Sold Shares Worth $111,776, According to a Recent SEC Filing	17-10-23
Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board	13-10-23
Bellerophon Therapeutics, Inc.(OTCPK:BLPH) dropped from NASDAQ Composite Index	13-10-23
North American Morning Briefing : Focus Shifts to -2-	21-08-23
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14-08-23
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading	28-07-23
Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director	14-07-23
Bellerophon Therapeutics : Costs Associated with Exit/Disposal - Form 8-K	29-06-23
Bellerophon Therapeutics Announces Separation of Peter Fernandes as Chief Executive Officer, Effective July 15, 2023	29-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Bellerophon Therapeutics LLC Nasdaq

Aandelen

Andere talen

Filters